Filing Flows › Idexx Laboratories (IDXX) › Q4 2025
Idexx Laboratories (IDXX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 20, 2026
Idexx Laboratories (IDXX) reported revenue of $1.1B for the fourth quarter 2025 (Q4 2025), +14% from a year earlier and -1% from the quarter before. Operating margin was 28.9%, net earnings $248M (22.8% of revenue).
Idexx Laboratories, Q4 2025: revenue $1.1B (+14% year over year), operating margin 28.9%, net earnings $248M, operating cash flow $356M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1B | -1% | +14% |
| Gross profit | $658M | -4% | +15% |
| Operating profit | $316M | -11% | +21% |
| Net earnings | $248M | -10% | +15% |
| Operating cash flow | $356M | -12% | +36% |
| Free cash flow | $326M | -12% | +40% |
What changed
Revenue was $1.1B in Q4 2025, up 14% year over year and down 1% from the previous quarter. Product revenue was the largest line at 60% of revenue.
Gross margin was 60.3%, up 0.5 points from a year earlier. Operating profit was $0.32B, a 28.9% margin (up 1.5 points year over year). Of the extra revenue versus a year earlier, 40% reached operating profit, above the 27% margin then. Operating expenses grew 11% against revenue growth of 14%. The fastest-growing cost line was Research & development (+16%). Net earnings were $0.25B, up 15% year over year. The effective tax rate was 19.2%.
Operating cash flow was $0.36B (up 36% year over year), 143% of net earnings. Non-cash charges added back $0.04B of depreciation and amortization and $0.02B of share-based compensation. Working capital and other items added $0.05B. Capital expenditures of $0.03B left free cash flow of $0.33B.
Questions
What was Idexx Laboratories' revenue in the fourth quarter 2025?
Idexx Laboratories (IDXX) reported revenue of $1.1B for the fourth quarter 2025 (Q4 2025), +14% from a year earlier and -1% from the quarter before.
Was Idexx Laboratories profitable in the fourth quarter 2025?
Operating profit was $316M (28.9% of revenue) and net earnings $248M.
Source: Idexx Laboratories 10-K on SEC EDGAR.